Sporet levering verden over | Forventet 9–14 hverdage

Din kurv

Din indkøbskurv er tom

Begynd at browse

Gratis fragt på ordrer over €500.

Subtotal€0
Gå til betaling
LevetidKlinisk

VIP

Publiceret forskning og dokumentationsgrundlag

Vasoactive intestinal peptide is a 28-amino-acid neuropeptide that signals through the class B G protein-coupled receptors VPAC1 and VPAC2, with documented roles in pulmonary vasodilation, surfactant regulation, suppression of pro-inflammatory cytokine release, regulatory T cell induction, and synchronisation of circadian pacemaker neurons in the suprachiasmatic nucleus. Its synthetic form, aviptadil, has been tested in humans for COVID-19-associated acute hypoxaemic respiratory failure, sarcoidosis and erectile dysfunction. The largest randomised trial in respiratory failure (TESICO) found no significant clinical benefit for intravenous aviptadil versus placebo, and a 2025 systematic review of ARDS trials reported a pooled survival odds ratio of 1.01, while smaller inhaled-route and open-label studies reported favourable but non-definitive signals. An aviptadil-phentolamine intracavernosal combination is an established second-line agent in erectile dysfunction practice.

Kort fortalt
  • VIP er et neuropeptid med 28 aminosyrer; den syntetiske form er aviptadil.
  • Humane forsøg testede aviptadil til COVID-19-respirationssvigt og sarkoidose.
  • Det største forsøg fandt ingen fordel, og metaanalysen viser ingen overlevelsesgevinst.

40 studier · 10 siden 2023 · nyeste 2026

Undersøgelser citeret
40
Publiceret 2023+
10
Nyeste artikel
2026
Sidst gennemgået
okt. 2026

Tilbagevendende temaer i litteraturen

  • VPAC1 and VPAC2 receptor pharmacology and cAMP signalling
  • Aviptadil in ARDS and COVID-19 respiratory failure (largely negative randomised evidence)
  • Pulmonary vasodilation and pulmonary arterial hypertension
  • Immunomodulation, TNF-alpha suppression and regulatory T cell induction
  • Circadian pacemaking and neuronal synchrony in the suprachiasmatic nucleus
  • Inhaled delivery for chronic lung inflammation (sarcoidosis)
  • Intracavernosal aviptadil-phentolamine for erectile dysfunction
  • Short plasma half-life and the search for long-acting analogues

Stofidentifikatorer

CAS
40077-57-4
PubChem
16132300

Kemisk identitet

Hvad VIP er, kemisk.

Molekylformel
C147H237N43O43S
Molekylvægt
3326.8 g/mol
CAS-nummer
40077-57-4
PubChem CID
16132300
Også skrevet som

invicorp

Disse tal stammer fra PubChem-posten for denne forbindelse og beskriver den frie base. Lyofiliseret peptid leveres normalt som et acetat- eller trifluoroacetatsalt og indeholder restvand, så massen af pulver i et hætteglas er ikke den samme mængde, som molekylvægten ovenfor ville antyde. Kromatografisk renhed på et analysecertifikat løser heller ikke den forskel — Sådan læses et analysecertifikat forklarer hvorfor.

Evidensen

40 offentliggjorte studier.

Sorteret efter styrken i studiedesignet og derefter efter nyhed. Hver post linker til sin kildepost, så fundet kan kontrolleres mod artiklen i stedet for at tages på vores ord.

  1. 01Systematisk gennemgang2025

    Aviptadil Therapy in Acute Respiratory Distress Syndrome Patients: A Systematic Review and Meta-analysis

    Udupa AA, et al. · Indian Journal of Critical Care Medicine · systematic review and meta-analysis of 9 studies (2 randomised controlled trials, 7 case series), 665 patients of whom 361 received aviptadil, search to October 2025

    Pooling the two randomised trials gave a survival odds ratio of 1.01 (95% CI 0.72-1.42, p=0.93), indicating no significant survival benefit for aviptadil over placebo in ARDS. Case series reported higher survival (88.9%) and improvements in oxygenation and inflammatory markers, but the authors noted these were uncontrolled.

  2. 02Humant klinisk2025

    Inhaled Aviptadil Is a New Hope for Recovery of Lung Damage due to COVID-19

    Esendagli D, et al. · Medical Principles and Practice · multicentre, prospective, double-blind, placebo-controlled randomised trial, 80 hospitalised adults with COVID-19 pneumonia across 9 centres

    Mean time to discharge was 7.8 days with inhaled aviptadil versus 10.0 days with placebo (p=0.049), and improvement in CT lung damage score at day 28 was greater in the aviptadil arm (p=0.028). No dropouts occurred due to adverse effects; the trial was small and subsequently drew published methodological critiques.

  3. 03Humant klinisk2025

    Intracavernosal injection of aviptadil and phentolamine for refractory erectile dysfunction

    Al-Mitwalli A, et al. · The Journal of Sexual Medicine · retrospective single-centre cohort, 308 men with erectile dysfunction refractory to or intolerant of alprostadil, mean follow-up 13.3 months

    Aviptadil-phentolamine intracavernosal injection was effective in 182 of 308 men (59%), with 76% efficacy among those switched for alprostadil-related pain versus 36% among alprostadil non-responders (p<0.0001). Facial flushing occurred in 22.5% and ischaemic priapism in one patient (0.3%).

  4. 04Humant klinisk2024

    Effect of Aviptadil, a Novel Therapy, on Clinical Outcomes of Patients with Viral-related Severe ARDS: A Retrospective Observational Study.

    Sampley S, et al. · Indian J Crit Care Med · retrospective observational study, 6 ICU patients with severe viral-related ARDS (out of 68 admitted with viral pneumonia) given intravenous aviptadil with conventional treatment, no control group

    Mean oxygen saturation rose from 87.86% to 93.43% and the SpO2/FiO2 ratio from 149 to 336 by the end of 3 days of infusion (p-value < 0.003), with improvement in PaO2 and radiological scores. No adverse effects were noted.

  5. 05Humant klinisk2023

    Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial

    Brown SM, et al. · The Lancet Respiratory Medicine · randomised placebo-controlled trial (ACTIV-3b/TESICO), 461 adults in the modified intention-to-treat aviptadil comparison, 28 US sites

    Intravenous aviptadil did not significantly improve clinical outcomes through day 90 compared with placebo; the odds ratio for a better category of the primary efficacy endpoint was 1.11 (95% CI 0.80-1.55, p=0.54). The authors concluded aviptadil showed no significant benefit in COVID-19-associated acute hypoxaemic respiratory failure.

  6. 06Humant klinisk2023

    The effect of Lu AG09222 on PACAP38- and VIP-induced vasodilation, heart rate increase, and headache in healthy subjects: an interventional, randomized, double-blind, parallel-group, placebo-controlled study

    Rasmussen NB, et al. · The Journal of Headache and Pain · randomised, double-blind, placebo-controlled interventional study, 25 healthy volunteers aged 18-45 receiving PACAP38 and VIP infusions

    Infused VIP and PACAP38 produced measurable cranial arterial vasodilation, increased facial blood flow and heart rate, and mild headache in healthy subjects. An anti-PACAP monoclonal antibody markedly reduced the PACAP38-driven responses, providing controlled human data on the acute haemodynamic actions of these peptides.

  7. 07Humant klinisk2022

    The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial

    Youssef JG, et al. · Critical Care Medicine · multicentre placebo-controlled randomised trial, 196 patients with COVID-19 respiratory failure, 2:1 allocation, 10 US hospitals

    The primary endpoint of being alive and free from respiratory failure at day 60 did not reach statistical significance (OR 1.6, 95% CI 0.86-3.11). A secondary analysis reported improved 60-day survival (OR 2.0, 95% CI 1.1-3.9, p=0.035) alongside reduced interleukin-6 release by day 3.

  8. 08Humant klinisk2021

    Effect of Vasoactive Intestinal Polypeptide on Development of Migraine Headaches: A Randomized Clinical Trial.

    Pellesi L, et al. · JAMA Netw Open · randomized double-blind placebo-controlled crossover trial, n=21 patients with migraine without aura, 2-hour infusion

    A 2-hour VIP infusion induced migraine attacks in 15 of 21 patients (71%) versus 1 (5%) after placebo, with greater headache intensity and superficial temporal artery dilation.

    Rapporteret sikkerhedsfund. A 2-hour VIP infusion provoked migraine attacks in 71% of migraine patients versus 5% with placebo.

  9. 09Humant klinisk2020

    The effect of pituitary adenylate cyclase-activating peptide-38 and vasoactive intestinal peptide in cluster headache.

    Vollesen ALH, et al. · Cephalalgia · randomised double-blind crossover provocation study (NCT03814226) in cluster headache: 14 episodic active-phase, 15 episodic remission-phase and 15 chronic patients, 20-minute intravenous infusions of VIP or PACAP38 on separate days

    VIP induced cluster-like attacks in 5 of 14 episodic active-phase patients and 7 of 15 chronic patients, rates similar to PACAP38 (6 of 14 and 7 of 15), and induced no attacks in remission-phase patients.

    Rapporteret sikkerhedsfund. Intravenous VIP provoked cluster-like attacks in 5 of 14 episodic active-phase and 7 of 15 chronic cluster headache patients.

  10. 10Humant klinisk2020

    Two-hour infusion of vasoactive intestinal polypeptide induces delayed headache and extracranial vasodilation in healthy volunteers.

    Pellesi L, et al. · Cephalalgia · double-blind placebo-controlled crossover study (NCT03989817), 12 healthy volunteers, 2-hour continuous intravenous VIP infusion

    Headache incidence was higher on the VIP day than the placebo day (p = 0.003), with mild delayed headaches mainly after the infusion, and superficial temporal artery dilation lasted more than 2 h (p < 0.001). Tear production, a marker of cranial parasympathetic activity, was higher during VIP (p = 0.033).

  11. 11Humant klinisk2010

    Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis

    Prasse A, et al. · American Journal of Respiratory and Critical Care Medicine · open-label phase II study, 20 patients with histologically confirmed active sarcoidosis, 4 weeks of nebulised VIP

    Inhaled VIP was well tolerated and significantly reduced TNF-alpha production by cells from bronchoalveolar lavage fluid, while increasing bronchoalveolar CD4+CD127-CD25+ regulatory T cells. This was the first demonstration of an immunoregulatory effect of VIP in humans.

  12. 12Humant klinisk2008

    Inhalation of vasoactive intestinal peptide in pulmonary hypertension.

    Leuchte HH, et al. · Eur Respir J · single-dose acute haemodynamic study, n=20 patients with pulmonary hypertension during right-heart catheterisation

    Inhaled aviptadil caused a small, short-lived selective pulmonary vasodilation with improved stroke volume and mixed venous oxygen saturation, without side effects or change in systemic blood pressure; 6 patients had a >20% reduction in pulmonary vascular resistance.

  13. 13Humant klinisk2008

    Vasoactive intestinal peptide causes marked cephalic vasodilation, but does not induce migraine.

    Rahmann A, et al. · Cephalalgia · randomised double-blind placebo-controlled crossover study, twelve patients with migraine without aura, intravenous VIP infusion

    No patient had a migraine attack after VIP, which caused only a mild immediate headache compared with placebo (P = 0.005); delayed headache occurred in three patients after VIP and two after placebo (P = 0.89). VIP dilated the superficial temporal artery by 45.9% and lowered middle cerebral artery flow velocity by 16.3%.

  14. 14Humant klinisk2007

    Injection therapy for the treatment of erectile dysfunction: a comparison between alprostadil and a combination of vasoactive intestinal polypeptide and phentolamine mesilate.

    Shah PJ, et al. · Curr Med Res Opin · open multicentre randomised crossover trial, n=187 men with erectile dysfunction (107 in phase 2)

    Both alprostadil and VIP/phentolamine produced intercourse-grade erections (83% vs 73% in dose-finding; 83-85% of injections in phase 2); VIP/phentolamine caused less injection pain (3% vs 28% of injections) but more facial flushing (16-17% vs 3%) and was preferred by more patients.

    Rapporteret sikkerhedsfund. Facial flushing followed 16-17% of VIP/phentolamine injections.

  15. 15Humant klinisk2006

    Vasoactive intestinal polypeptide evokes only a minimal headache in healthy volunteers.

    Hansen JM, et al. · Cephalalgia · double-blind placebo-controlled crossover study, 12 healthy young volunteers, 25-minute intravenous VIP infusion

    Headache was very mild (maximum score 2 of 10); five participants developed headache with VIP and one with placebo. VIP caused marked superficial temporal artery dilation (P = 0.04), a transient fall in middle cerebral artery flow velocity (P < 0.001) and a rise in heart rate, without a significant change in regional cerebral blood flow.

  16. 16Humant klinisk2003

    Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension.

    Petkov V, et al. · J Clin Invest · serum/lung tissue analysis plus open treatment study, n=8 patients with primary pulmonary hypertension

    Patients showed VIP deficiency in serum and lung tissue with upregulated VIP receptors; VIP substitution decreased mean pulmonary artery pressure and increased cardiac output and mixed venous oxygen saturation without reported side effects.

  17. 17Humant klinisk1999

    A double blind, placebo controlled study of intracavernosal vasoactive intestinal polypeptide and phenotolamine mesylate in a novel auto-injector for the treatment of non-psychogenic erectile dysfunction.

    Sandhu D, et al. · Int J Impot Res · double-blind placebo-controlled study, n=304 in dose-assessment and n=195 in placebo-controlled phase, non-psychogenic erectile dysfunction, auto-injector

    VIP/phentolamine produced intercourse-suitable erections in 75.1% and 66.5% of patients (two phentolamine strengths) versus 12% and 10.3% on placebo; transient facial flushing followed 33.9% of injections, priapism occurred twice (0.05%), and nine patients withdrew for adverse events.

    Rapporteret sikkerhedsfund. Transient facial flushing followed about one-third of injections; priapism occurred in 0.05% of injections.

  18. 18Humant klinisk1999

    Treating men with predominantly nonpsychogenic erectile dysfunction with intracavernosal vasoactive intestinal polypeptide and phentolamine mesylate in a novel auto-injector system: a multicentre double-blind placebo-controlled study.

    Dinsmore WW, et al. · BJU Int · multicentre double-blind placebo-controlled study at eight institutions, 236 men with primarily non-psychogenic erectile dysfunction; intracavernosal VIP combined with phentolamine (the aviptadil-phentolamine combination sold as Invicorp) by auto-injector, a dose-assessment phase then a 6-month placebo-controlled phase in 171 men

    In the placebo-controlled phase 75% responded to the combination with the lower phentolamine strength versus 12% on placebo, and 66% to the higher strength versus 18% on placebo (P<0.001). Transient facial flushing accompanied 40% of 1711 injections, there was one episode of priapism (0.06%) and seven patients withdrew because of adverse events.

    Rapporteret sikkerhedsfund. Transient facial flushing accompanied 40% of injections and one episode of priapism (0.06%) occurred.

  19. 19Humant klinisk1998

    Venous ulcers: improved healing by iontophoretic administration of calcitonin gene-related peptide and vasoactive intestinal polypeptide.

    Gherardini G, et al. · Plast Reconstr Surg · randomised placebo-controlled trial, 66 patients with venous leg ulcers, iontophoresis of calcitonin gene-related peptide plus VIP versus placebo iontophoresis on top of standard treatment, 12 weeks

    The percentage of ulcer area healed and the number of healed ulcers improved significantly more with CGRP plus VIP iontophoresis than with placebo iontophoresis over 12 weeks.

  20. 20Humant klinisk1998

    Vasoactive intestinal polypeptide and phentolamine mesylate administered by autoinjector in the treatment of patients with erectile dysfunction resistant to other intracavernosal agents.

    Dinsmore WW, Alderdice DK · Br J Urol · consecutive case series, 70 men with erectile dysfunction in whom intracavernosal prostaglandin E1 and papaverine with phentolamine had failed, VIP combined with phentolamine (Invicorp combination) by autoinjector in clinic and then at home

    Forty-seven patients (67%) achieved erections sufficient for intercourse. Side effects were transient facial flushing in 37 (53%), truncal flushing in six (9%), bruising in 14 (20%) and needle pain in eight (11%); no priapism or other serious adverse events were reported.

  21. 21Humant klinisk1993

    Effect of vasoactive intestinal polypeptide (VIP) on pulmonary ventilation-perfusion relationships and central haemodynamics in healthy subjects.

    Söderman C, et al. · Clin Physiol · experimental study, nine healthy subjects, 30-minute intravenous VIP infusion with inert-gas ventilation-perfusion and central haemodynamic measurements

    Pulmonary vascular resistance fell by 25% and systemic vascular resistance by 53%, while cardiac output rose 80% and heart rate 27%. Ventilation-perfusion distributions shifted to lower values but no shunt or hypoxaemia developed.

  22. 22Humant klinisk1992

    The effect of vasoactive intestinal polypeptide on the lower esophageal sphincter in achalasia.

    Guelrud M, et al. · Gastroenterology · placebo-controlled manometry study of intravenous VIP at three doses, six patients with achalasia and four healthy volunteers

    In achalasia VIP caused a dose-dependent fall in lower oesophageal sphincter pressure (maximal decrease 51%) with improved sphincter relaxation, whereas it had no effect on oesophageal motility in healthy volunteers.

  23. 23Humant klinisk1992

    Intracavernous self-injection with vasoactive intestinal polypeptide and phentolamine in the management of erectile failure.

    Gerstenberg TC, et al. · J Urol · case series, 52 men with erectile failure of mixed aetiology using intracavernous self-injection of VIP combined with phentolamine, 1,380 self-injections, median 6 months of treatment

    All patients obtained erections sufficient for penetration after sexual stimulation, with no priapism, corporeal fibrosis or other serious complications. Nine patients discontinued, one because of palpitation and sweating, and one death from myocardial infarction was reported as not associated with the therapy.

  24. 24Humant klinisk1990

    A clinical trial of intracavernous vasoactive intestinal peptide to induce penile erection.

    Roy JB, et al. · J Urol · randomised double-blind placebo-controlled trial, 24 men with diabetic, neurogenic or psychogenic erectile dysfunction, intracavernous VIP alone at two dose levels or placebo

    VIP produced significant dose-related increases in penile length (p = 0.01) and diameter (p = 0.001), but none of the patients achieved rigidity adequate for intromission.

  25. 25Humant klinisk1988

    Effects of vasoactive intestinal polypeptide infusions on renal function in patients with liver disease.

    Calam J, et al. · Clin Exp Pharmacol Physiol · infusion study, six patients with cirrhosis of the liver, intravenous VIP

    VIP caused generalised vasodilation and raised plasma renin activity but reduced glomerular filtration rate by about one third, with significant falls in the excretion of water, sodium, potassium and calcium.

    Rapporteret sikkerhedsfund. In patients with cirrhosis, VIP infusion reduced glomerular filtration rate by about one third.

  26. 26Humant klinisk1987

    Effects of indomethacin and (+/-)-propranolol on the cardiovascular and renin responses to vasoactive intestinal polypeptide (VIP) infusion in man.

    Unwin RJ, et al. · Br J Clin Pharmacol · two randomised single-blind crossover studies, two groups of six healthy male volunteers aged 24-35, intravenous VIP infusion after indomethacin, propranolol or no pretreatment

    VIP infusion produced cutaneous flushing, increased heart rate and plasma renin activity and lowered forearm vascular resistance without changing mean arterial pressure. Indomethacin and propranolol did not change the percentage responses, and the authors concluded the responses were direct rather than reflex.

  27. 27Humant klinisk1986

    Vasoactive intestinal peptide as a bronchodilator in severe asthma.

    Morice AH, Sever PS · Peptides · two studies in two groups of eight in-patient volunteers recovering from severe acute asthma, intravenous VIP infusion compared with salbutamol and after ipratropium pretreatment

    VIP raised peak expiratory flow by 26 l/min after 30 minutes of infusion (p < 0.01), less than the 39 l/min seen with salbutamol, and still produced bronchodilation of 25 l/min after ipratropium (p < 0.02). The authors concluded VIP is a bronchodilator in severe asthma but weaker than conventional medication.

  28. 28Humant klinisk1984

    The effect of inhaled vasoactive intestinal peptide on bronchial reactivity to histamine in humans.

    Barnes PJ, Dixon CM · Am Rev Respir Dis · randomised double-blind crossover study, 6 atopic asthmatic subjects, inhaled VIP versus control solution and salbutamol on separate days

    Inhaled VIP did not change specific airway conductance but more than doubled the histamine concentration needed to reduce conductance by 35% (PC35 from 2.18 to 5.00, p < 0.05), a smaller protective effect than salbutamol. Heart rate and blood pressure did not change.

  29. 29Humant klinisk1984

    Vasoactive intestinal peptide as a bronchodilator in asthmatic subjects.

    Morice AH, et al. · Peptides · double-blind placebo-controlled study, 7 asthmatic volunteers, 15-minute intravenous VIP infusion followed by histamine challenge

    FEV1 rose by a mean 0.21 l after the 15-minute infusion, and VIP reduced the fall in FEV1 after histamine challenge compared with placebo. Tachycardia and cutaneous flushing occurred during the infusion.

  30. 30Humant klinisk1983

    Production of secretory diarrhea by intravenous infusion of vasoactive intestinal polypeptide.

    Kane MG, et al. · N Engl J Med · experimental infusion study, five healthy non-fasting subjects, 10-hour continuous intravenous VIP infusion

    Plasma VIP rose into the range seen in pancreatic cholera syndrome, and all five subjects developed profuse watery diarrhoea within a mean 4.3 hours, with mean stool weight of 2441 g at 10 hours. Faecal bicarbonate loss caused hyperchloraemic metabolic acidosis.

    Rapporteret sikkerhedsfund. Prolonged intravenous VIP infusion caused profuse secretory diarrhoea and metabolic acidosis in all five healthy subjects.

  31. 31Humant klinisk1981

    Infusion of vasoactive intestinal polypeptide in man: pharmacokinetics and effect on gastric acid secretion.

    Holm-Bentzen M, et al. · Scand J Gastroenterol · pharmacokinetic study, six healthy volunteers, stepwise intravenous VIP infusion on a pentagastrin background

    VIP elimination was bi-exponential with half-lives of 2 and 21 min, and plasma VIP rose with each infusion step. Gastric acid secretion and serum gastrin did not change.

  32. 32Dyr in vivo2026

    Heterogeneity between VIP and GRP neurons underlies AVP receptor signaling in the mouse suprachiasmatic nucleus

    Zhou H, et al. · Communications Biology · mouse suprachiasmatic nucleus, cell-type-specific expression mapping and conditional V1a deletion with a jet-lag behavioural paradigm

    Only a small subpopulation of VIP-ergic ventral suprachiasmatic neurons expressed the vasopressin V1a receptor, and V1a in those VIP neurons was required to maintain circadian robustness in a jet-lag paradigm. V1a expression was minimal in the neighbouring gastrin-releasing peptide population, indicating functional heterogeneity within the ventral SCN.

  33. 33Dyr in vivo2007

    Moderate pulmonary arterial hypertension in male mice lacking the vasoactive intestinal peptide gene

    Said SI, et al. · Circulation · VIP gene knockout (VIP-/-) mice versus wild-type controls, haemodynamic and histological assessment

    VIP-knockout mice developed moderate right ventricular hypertension, right ventricular hypertrophy and pulmonary vascular remodelling with increased muscularisation and perivascular inflammatory infiltrates, in the absence of systemic hypertension or hypoxaemia. The findings supported VIP deficiency as a contributor to pulmonary arterial hypertension.

  34. 34Dyr in vivo2005

    Vasoactive intestinal polypeptide mediates circadian rhythmicity and synchrony in mammalian clock neurons

    Aton SJ, et al. · Nature Neuroscience · Vip-/- and Vipr2-/- knockout mice, behavioural recording plus multielectrode recording of suprachiasmatic nucleus neurons

    Loss of VIP or the VPAC2 receptor abolished circadian firing rhythms in roughly half of suprachiasmatic nucleus neurons and disrupted synchrony between the remaining rhythmic neurons. Daily application of a VPAC2 agonist restored rhythmicity and synchrony in Vip-/- but not Vipr2-/- slices.

  35. 35In vitro2026

    Finding functional gaps: integrative analysis of VPAC1- and VPAC2-mediated signalling pathways in human lymphocytes

    Cabrera-Martín A, et al. · Cell & Bioscience · BRET receptor-G protein coupling assays and stable Jurkat T-cell lines overexpressing VPAC1 or VPAC2

    VPAC1 was shown to couple to both Galpha-s and Galpha-q subunits, and the two receptors produced distinguishable second-messenger, kinase-phosphorylation and immune-mediator transcriptional profiles in T cells. The study mapped functional differences between VPAC1 and VPAC2 signalling in a human lymphocyte background.

  36. 36Gennemgang2026

    A Historical Review of Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-Activating Polypeptide in Sepsis

    Dawlaty R, et al. · Biology (Basel) · historical narrative review spanning five decades of VIP and PACAP sepsis research

    The review traced VIP and PACAP from early endotoxemia studies, where rising VIP correlated with hypotension and mortality, to their later classification as macrophage-deactivating factors that downregulate TNF-alpha and IL-6. It concluded that the net effect is context-dependent, varying with timing, tissue compartment and inflammatory state.

  37. 37Gennemgang2023

    The role of vasoactive intestinal peptide in pulmonary diseases

    Zhong HL, et al. · Life Sciences · narrative review of VIP across pulmonary disease states

    The review surveyed VIP in pulmonary arterial hypertension, COPD, asthma, cystic fibrosis, acute lung injury/ARDS, pulmonary fibrosis and lung tumours. It identified rapid degradation and short duration of action as the principal limitations of native VIP as a therapeutic and summarised extended-release formulations and analogues under investigation.

  38. 38Gennemgang2012

    Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1

    Harmar AJ, et al. · British Journal of Pharmacology · IUPHAR consensus receptor pharmacology review

    The review established the nomenclature and pharmacology of the three class B receptors PAC1, VPAC1 and VPAC2, noting that PAC1 is PACAP-selective while VPAC1 and VPAC2 bind both VIP and PACAP with high affinity. It catalogued roles spanning circadian rhythm control, immune regulation and smooth muscle relaxation.

  39. 39Gennemgang2008

    Vasoactive intestinal polypeptide/phentolamine for intracavernosal injection in erectile dysfunction

    Dinsmore WW, Wyllie MG · BJU International · narrative review of the aviptadil/phentolamine (Invicorp) intracavernosal combination

    The review summarised the pharmacological rationale and clinical development of the VIP/phentolamine intracavernosal combination as an alternative to alprostadil, emphasising its lower incidence of injection-site pain.

  40. 40Caserapport2022

    Brief Report: Rapid Clinical Recovery From Critical Coronavirus Disease 2019 With Respiratory Failure in a Pregnant Patient Treated With IV Vasoactive Intestinal Peptide.

    Youssef JG, et al. · Crit Care Explor · single case, 32-year-old woman at 27 weeks' gestation with critical COVID-19 respiratory failure, intravenous aviptadil under an FDA expanded-access protocol (NCT04453839), followed for 4 months

    Aviptadil was given alongside remdesivir, methylprednisolone, enoxaparin and inhaled epoprostenol with continuous fetal monitoring, and the authors reported rapid clinical improvement. The abstract gives no outcome numbers.

Begrænsninger

Hvad denne evidens ikke fastslår.

The largest and most rigorous randomised trial of intravenous aviptadil in COVID-19 respiratory failure was negative, and meta-analysis of the randomised evidence shows no survival benefit in ARDS, so positive signals from small inhaled-route trials, case series and retrospective cohorts remain unconfirmed. No adequately powered randomised outcome trials exist for VIP or aviptadil in pulmonary arterial hypertension or sarcoidosis; native VIP has a very short plasma half-life, and long-acting analogues such as PB1046 (vasomera) have no primary peer-reviewed trial reports indexed in PubMed as of August 2026.

Almindelige spørgsmål om forskningen.

What is VIP?

VIP is vasoactive intestinal peptide, a 28-amino-acid neuropeptide isolated from porcine small intestine in 1970 and named for the vasodilator activity that first identified it. It signals through the VPAC1 and VPAC2 receptors and is studied in both vascular and immunological research.

Why does the literature use an intranasal route as well as injection?

The native peptide has a short circulating half-life, so published work has explored delivery routes that reach target tissue more directly — inhaled delivery in the pulmonary studies, and intranasal administration elsewhere in the neuropeptide literature. Both routes appear as study design choices, not as evidence that one outperforms the other.

How does VIP relate to PACAP and secretin?

All three belong to the secretin/glucagon peptide superfamily and share receptor overlap. PACAP binds PAC1 with high affinity and also engages VPAC1 and VPAC2; VIP has the reverse preference, favouring VPAC1 and VPAC2 with lower PAC1 affinity. The distinction matters when interpreting studies that use one ligand to infer the behaviour of another.

Fås i vores katalog

Kun til forskningsformål. Ikke til humant forbrug, diagnose, behandling eller forebyggelse af nogen tilstand. Intet på denne side er medicinsk rådgivning, og intet studie opsummeret her skal læses som en anbefaling.